Perella Weinberg Partners Capital Management’s Teva Pharmaceuticals TEVA Stock Holding History

Perella Weinberg Partners Capital Management’s Portfolio TEVA Stock Details TEVA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q3	–	Sell	-13,700	Closed	-$126K	–	148
2019 Q2	$126K	Buy	+13,700	New	+$165K	0.01%	219
2018 Q4	–	Sell	-120,488	Closed	-$2.6M	–	216
2018 Q3	$2.6M	Buy	+120,488	New	+$2.8M	0.12%	126
2018 Q2	–	Sell	-76,003	Closed	-$1.3M	–	248
2018 Q1	$1.3M	Buy	+76,003	New	+$1.48M	0.06%	173
2017 Q2	–	Sell	-31,094	Closed	-$997K	–	176
2017 Q1	$997K	Buy	+31,094	New	+$1.06M	0.16%	98
2016 Q3	–	Sell	-12,111	Closed	-$608K	–	85
2016 Q2	$608K	Buy	+12,111	New	+$645K	0.3%	40
2016 Q1	–	Sell	-10,000	Closed	-$656K	–	67
2015 Q4	$656K	Buy	+10,000	New	+$618K	0.22%	48

Other funds holding TEVA

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Berkshire Hathaway Omaha, Nebraska $263B AUM 16.68% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

ACM

Abrams Capital Management Boston, Massachusetts $4.64B AUM 1.52% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return

Commerzbank Aktiengesellschaft Frankfurt, Germany $5B AUM 26.58% 1-Year Est. Return

Perella Weinberg Partners Capital Management's TEVA Position: Q3 2019 in Review

Perella Weinberg Partners Capital Management sold out of Teva Pharmaceuticals (TEVA) in Q3 2019, closing a stake of 13,700 shares — an estimated $126K sold.

Perella Weinberg Partners Capital Management first reported a position in TEVA in Q4 2015 and held it in 6 quarters. The position peaked at $2.6M in Q3 2018. 428 funds tracked by Wall St. Rank hold TEVA as of Q3 2019.

Perella Weinberg Partners Capital Management reported no remaining Teva Pharmaceuticals position as of Q3 2019 after selling out during the quarter.
Perella Weinberg Partners Capital Management sold 13,700 Teva Pharmaceuticals shares in Q3 2019, an estimated $126K.
Perella Weinberg Partners Capital Management first reported a position in Teva Pharmaceuticals in Q4 2015 and held it in 6 quarters.
Perella Weinberg Partners Capital Management's Teva Pharmaceuticals position peaked at $2.6M in Q3 2018.
428 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q3 2019.

Based on Perella Weinberg Partners Capital Management's 13F filing for Q3 2019, filed 8 Nov 2019.